Overview
- The Federal Trade Commission filed a complaint July 29 in federal court and was joined by Utah and Los Angeles County in accusing Hims & Hers of misleading consumers about privacy and billing.
- Regulators say the company transmitted users’ health‑related activity to advertising platforms by using tracking tools such as Meta Pixel, Meta Conversions API and by sharing customer lists with partners including Meta and Snap.
- The complaint alleges Hims & Hers routinely charged customers for prescription subscriptions shortly after intake forms and before clinicians reviewed cases, and that the company buried or made cancellation options hard to find.
- Hims & Hers denies the allegations and says it will vigorously defend itself while the company’s stock dropped sharply on the news, reflecting investor concern about potential fines and reputational harm.
- The FTC and state plaintiffs seek a permanent injunction, consumer restitution and civil penalties, and the case could reshape how telehealth firms use third‑party ad tech and design intake and billing flows.